Skip to main content
Industry News
Ensartinib better than crizotinib in ALK-positive NSCLC

Individuals with anaplastic lymphoma kinase-positive non-small cell lung cancer who received ensartinib had 25.8 months median progression-free survival, compared with 12.7 months median PFS among those who were given crizotinib, study results show. "Ensartinib showed superior efficacy in the brain over crizotinib and represents a new first-line treatment option for patients with ALK-positive NSCLC," said researcher Dr. Leora Horn.

Full Story: